Abstract Library

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4592 Uncovering cell-state heterogeneity in large-cell panNEC indicates potentially targetable aberrant brain type neuronal de-differentiation

Introduction: Classification and treatment of high-grade pancreatic neuroendocrine carcinoma (panNEC), particularly those with large-cell morphology, present significant clinical challenges due to considerable inter- and intra-patient tumour heterogeneity.

Conference:

Presenting Author: Debnath O

Authors: Debnath O, Berger H, Detjen K, Kirchner P, Marinoni I,

Keywords: pancreatic neuroendocrine carcinoma, single cell, personalised medicine,

#4361 Identification of IRS2 as a prognostic and therapeutic target in gastrointestinal neuroendocrine tumours

Introduction: Intestinal neuroendocrine tumours (INETs) are rare malignancies characterised by diverse clinical outcomes. In our previous research, high expression of IRS2 was associated with poor prognosis in gastric neuroendocrine tumours, but its role in intestinal neuroendocrine tumours remains unclear.

Conference:

Presenting Author:

Authors: Zhang M, Li S,

Keywords: gastrointestinal neuroendocrine tumour, IRS2, tumour progression,

#4258 Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets

Introduction: High-grade pancreatic neuroendocrine carcinoma (panNEC) pose challenges in terms of classification and treatment. While molecular genetics have made strides in deciphering significant inter-tumor heterogeneity, the extent of intra-tumoral heterogeneity and lineage plasticity remains unexplored.

Conference:

Presenting Author:

Authors: Debnath O, Detjen K, Berger H, Kirchner P, Marinoni I,

Keywords: PanNEC, Single cell RNAseq,

#4206 Specific spliceosomic landscapes reveal a possible link between RNA processing and panNETs behaviour

Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) are characterized by a low number of mutations. Despite genomics, transcriptomics and epigenomics studies have helped to understand the molecular features of PanNETs, there is still a vast unexplored ground for better comprehension of this disease. In this context, we have previously documented that RNA splicing is dysregulated in these tumors, which unveils new avenues to discover potential biomarkers and therapeutic targets. However, clinical and molecular implications of this dysregulation are still very poorly understood.

Conference:

Presenting Author: Pedraza-Arévalo S

Authors: Pedraza-Arévalo S, Blázquez-Encinas R, García-Vioque V, Moreno-Montilla M, Ruiz-Palacios D,

Keywords: pancreatic neuroendocrine tumor, splicing, RNA, grade, metastasis,